Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.

Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Roche launches three respiratory panels in CE markets

November 2021—Roche launched in the CE market three molecular PCR diagnostic test panels to simultaneously detect and differentiate flu A, flu B, and respiratory syncytial virus; adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and parainfluenza 1, 2, 3, and 4. The tests can be run together or individually from a single nasopharyngeal swab specimen and run on the Cobas Omni Utility Channel for use with the Cobas 6800/8800 systems.

Bio-Rad launches CFX Opus Dx RT-PCR detection systems

November 2021—Bio-Rad launched its CFX Opus 96 Dx and CFX Opus 384 Dx systems, real-time PCR detection systems that have been listed with the FDA for IVD testing and that meet the CE-IVD requirement for IVD use in Europe. Both instruments are also registered with regulatory bodies for IVD use in Singapore and Canada.

Thermo Fisher appointed U.S. distributor of APAS Independence

November 2021—Clever Culture Systems signed a five-year agreement for Remel, a part of Thermo Fisher, to be the exclusive U.S. distributor of the APAS Independence. The FDA-cleared automated culture plate reader will be added to Thermo Fisher’s portfolio of microbiology products in the United States. Under the agreement, Thermo Fisher will provide sales and marketing, installation, maintenance, and support services to customers in the United States.

Hardy Diagnostics releases group A strep agar

November 2021—Hardy Diagnostics released its HardyChrom Group A Strep agar, a chromogenic medium recommended for the selective cultivation and differentiation of group A streptococcus from clinical specimens. Identification can be made based on colony color—the medium will display red-brown or red-orange colonies on the Hardy­Chrom Group A Strep agar when Streptococcus pyogenes is present; non-group A streptococcus isolates will appear as blue, clear, or white colonies.

PerkinElmer gets EUA for SARS-CoV-2 respiratory panel, ELISA

November 2021—PerkinElmer announced that the FDA has issued emergency use authorization for its PKamp Respiratory SARS-CoV-2 RT-PCR Panel 1 assay. The RT-PCR test provides simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus isolated from nasopharyngeal swabs, anterior nasal swabs, and midturbinate swabs.

ASI acquires line of nonmammalian blocking buffers

November 2021—Arlington Scientific has acquired a nonmammalian blocking buffer product line from Clark McDermith, former owner of EastCoast Bio. Arlington Scientific will be the exclusive worldwide manufacturer of the proprietary blocking buffers.

Simplexa COVID-19, flu A/B assay gets CE mark

November 2021—DiaSorin Molecular announced that it has CE marked its Simplexa COVID-19 and Flu A/B Direct kit. The multiplex test allows for the in vitro qualitative detection and differentiation of nucleic acid from SARS-CoV-2, influenza A, and influenza B from a patient sample in one reaction well. The assay is designed for use on the Liaison MDX and is run directly from nasopharyngeal swabs without the need for off-board extraction.

BD FACSymphony A1 Cell Analyzer

October 2021—BD launched the BD FACSymphony A1 Cell Analyzer, a fluorescence-activated cell analyzer that offers advanced research capabilities in a benchtop design. Fluorescence-activated cell sorter (FACS) technology enables precise isolation of selected single cells from complex samples.

Siemens launches Sysmex CN-3000, CN-6000 hemostasis systems

October 2021—Siemens Healthineers has launched Sysmex’s CN-3000 and CN-6000 hemostasis systems for mid- and high-volume coagulation testing. A broad menu of Siemens’ routine and specialty coagulation assays that help identify blood coagulation disorders such as abnormal blood clotting or bleeding, including Siemens’ Innovance Anti-Xa assay for heparin and direct oral anticoagulant testing, can be performed on the CN-3000 and CN-6000 instruments.

MARKETPLACE

TRENDING